Reported 2 months ago
Novavax has revised its 2024 revenue forecast downwards, anticipating lower sales of its COVID-19 vaccine, including a new shot targeting the JN.1 variant. The company now expects product sales of $275 to $375 million, down from its prior estimate of $400 to $600 million. The adjustments come as Novavax struggles to compete with leading companies like Pfizer and Moderna, resulting in a drop in its shares and disappointing quarterly results.
Source: YAHOO